Ana Babic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Babic has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Ann H. Partridge
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
4 shared publications - Bicky Thapa
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215-5450, USA Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA
4 shared publications - Brian D. Crompton
Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
4 shared publications - Catherine R. Marinac
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
4 shared publications - Colleen M. Feltmate
Harvard Medical School, Boston, Massachusetts
4 shared publications - Dipanjan Chowdhury
Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background:The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer.Methods:The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process.Results:Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample.Conclusions:The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development.Impact:Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 3 June 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (7) , OF1-OF12
A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study
Background: The InAdvance Study addresses the critical need for comprehensive data and biospecimen collection from individuals at elevated risk for cancer. Despite the existence of numerous biobanks for patients with cancer and individuals at average risk for cancer, a gap persists in resources targeting individuals with an elevated risk for cancer. Methods: The InAdvance Study is longitudinally collecting biospecimens and health data from individuals with a range of cancer risk factors to facilitate collaborative research in cancer early detection and interception. Patient populations include those with precancerous or precursor lesions (e.g., oral precursor lesions and Barrett's esophagus), hereditary cancer risk, personal or family history of cancer, or a history of exposures associated with cancer risk. Additionally, we are enrolling patients receiving multicancer early detection (MCED) tests, family members of elevated risk participants, and controls. Key goals include optimized biospecimen collection through standardized procedures, participant enrollment and engagement through an online platform, and standardized scalable procedures. Data are compiled into a central repository, and researchers can request access through a streamlined data request process. Results: Since April 2023, 1,415 participants have enrolled in the study. In total, 817 (58%) completed the baseline survey, and 816 (58%) gave a baseline blood sample. Conclusions: The InAdvance Study’s comprehensive approach provides a framework for basic, population, and translational studies to elucidate the molecular and environmental factors that drive cancer development. Impact: Comprehensive data and biospecimen biorepositories are critical to informing strategies for early detection, risk stratification, early interception for risk mitigation, and improved outcomes for higher-risk populations.
- 18 June 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (1) , 85-94
Associations between common contraceptive use and circulating inflammatory biomarkers
Ovarian cancer incidence has declined in recent decades, due in part to oral contraceptive (OC) use and tubal ligation. However, intrauterine device (IUD) use has increasingly replaced OC use. As ovarian cancer is an inflammation-related disease, we examined the association of OC use, IUD use, and tubal ligation with plasma levels of C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor α receptor 2 (sTNFR2), in the Nurses’ Health Study (NHS) and NHSII. After adjusting for reproductive, hormonal, and lifestyle factors, and mutual adjustment for other methods of contraception, there were no differences in inflammatory markers between ever and never use of each method. However, CRP levels decreased from an average 30.4% (-53.6, 4.4) with every 5 years since initial IUD use (P-trend=0.03), while CRP increased an average 9.9% (95% CI: 5.7, 14.3) with every 5 years of use of OC (P-trend<0.0001) as well as differences by BMI and menopausal status. Our results suggest IUD use and tubal ligation are not associated with higher circulating inflammatory markers long term, although long duration of OC use may increase generalized inflammation, which may in part explain why its protective effect wanes over time.
- 18 June 2024
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 194 (1) , 85-94
Associations between common contraceptive use and circulating inflammatory biomarkers
Ovarian cancer incidence has declined in recent decades, due in part to oral contraceptive (OC) use and tubal ligation. However, intrauterine device (IUD) use has increasingly replaced OC use. As ovarian cancer is an inflammation-related disease, we examined the association of OC use, IUD use, and tubal ligation with plasma levels of C-reactive protein (CRP), interleukin 6 (IL-6), and soluble tumor necrosis factor α receptor 2 (sTNFR2), in the Nurses’ Health Study (NHS) and NHSII. After adjusting for reproductive, hormonal, and lifestyle factors, and mutual adjustment for other methods of contraception, there were no differences in inflammatory markers between ever and never use of each method. However, CRP levels decreased from an average 30.4% (-53.6, 4.4) with every 5 years since initial IUD use (P-trend=0.03), while CRP increased an average 9.9% (95% CI: 5.7, 14.3) with every 5 years of use of OC (P-trend<0.0001) as well as differences by BMI and menopausal status. Our results suggest IUD use and tubal ligation are not associated with higher circulating inflammatory markers long term, although long duration of OC use may increase generalized inflammation, which may in part explain why its protective effect wanes over time.